← All trials
NCT02950467
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2017
- Primary completion
- Jul 1, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
- University of California, San FranciscoStudy director
- Heffter Research InstituteCollaborator
- River Styx FoundationCollaborator
- Usona InstituteCollaborator
- Stupski FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.